Human menopausal gonadotropin is a substance extracted from the urine of
menopausal women, containing follicle stimulating hormone and luteinizing
hormone. Its role in promoting follicle development is mainly follicle
stimulating hormone, which can be used in the treatment of polycystic ovary
syndrome.
Human menopause gonadotropin treatment of polycystic ovary syndrome
Intramuscular injection of 2 needles (each containing 75 units of follicle
stimulating hormone / 75 units of luteinizing hormone) per day should be
administered from the second to third day of menstruation. Patients with poor
follicular development can be indicated by b-ultrasound after 5-7 days. The dose
should be increased to 3 or 4 needles per day. When the follicles reach 18 --
20mm, gonadotropin 5000 -- 10,000 units can be intramuscular injected to induce
ovulation. Treatment should be carried out under the close supervision of
ultrasound and blood estradiol.
The indication of gonadotropin in human menopause
Amenorrhea patients; The basal body temperature does not rise even if there
is ovulation, the application of human menopause gonadotropin can increase the
pregnancy rate; Artificial insemination, gamete transplantation, hyperovulation
induction during in vitro fertilization.
Gonadotropin assists gonadotropin releasing hormone in the treatment of
human menopause
A large dose of gonadotropin-releasing hormone-a was injected
subcutaneously once A day for 4 weeks, followed by use of menopausal
gonadotropin-stimulating follicular development.
Tips: human gonadotropin during menopause can promote ovulation in patients
with polycystic ovary syndrome, so as to achieve the effect of treatment.